Clinical Trials
11 trialsNCT04946370 2026-04-21
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT07027124 2026-03-19
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT05787587 2026-02-09
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT03753243 2022-04-20
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Portland VA Medical Center
Phase 2 Recruiting